VRTX beat EPS expectations by 7.76%
May 05, 2025, 10:34 PM
0.00%
What does VRTX do
Vertex Pharmaceuticals, headquartered in Boston, specializes in developing small molecule drugs for serious diseases, with four approved cystic fibrosis treatments and therapies for sickle cell disease. The company employs 5,400 people and explores innovative treatments for various conditions, including type 1 diabetes.
Vertex Pharmaceuticals (VRTX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Vertex Pharmaceuticals's actual EPS was $4.06, beating the estimate of $4.37 per share, resulting in a 7.76% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.